Sensitivity of serum S100B protein as a disease activity marker in Egyptian patients with vitiligo (case-control study)

References

• Allam, M., and Riad, H., 2013. Concise review of recent studies in vitiligo. Qatar medical journal, 2013 (2), 10.
   Google Scholar
• Bang, J.S., et al., 2000. Comparative clinical study of segmental vitiligo and non-segmental vitiligo. Korean journal of dermatology, 38 (8), 1037–1044.
   Google Scholar
• Cheong, K.A., et al., 2014. S100B as a potential biomarker for the detection of cytotoxicity of melanocytes. Experimental dermatology, 23 (3), 165–171.
   PubMed Web of Science ®Google Scholar
• Cunliffe, W., et al., 1968. Vitiligo, thyroid disease and autoimmunity. British journal of dermatology, 80 (3), 135–139.
   PubMed Web of Science ®Google Scholar
• DeLong, E.R., DeLong, D.M., and Clarke-Pearson, D.L., 1988. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics, 44 (3), 837–845.
   PubMed Web of Science ®Google Scholar
• Feily, A., 2014. Vitiligo Extent Tensity Index (VETI) score: a new definition, assessment and treatment evaluation criteria in vitiligo. Dermatology practical and conceptual, 4 (4), 81.
   PubMedGoogle Scholar
• Fujiya, A., et al., 2014. The role of S100B in the interaction between adipocytes and macrophages. Obesity, 22 (2), 371–379.
   PubMed Web of Science ®Google Scholar
• Ghanem, G., et al., 2001. On the release and half‐life of S100B protein in the peripheral blood of melanoma patients. International journal of cancer, 94 (4), 586–590.
   PubMed Web of Science ®Google Scholar
• Hanley, J.A., and McNeil, B.J., 1983. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology, 148 (3), 839–843.
   PubMed Web of Science ®Google Scholar
• Homan, M.W.L., et al., 2009. The burden of vitiligo: patient characteristics associated with quality of life. Journal of the American academy of dermatology, 61 (3), 411–420.
   PubMed Web of Science ®Google Scholar
• Huggins, R.H., Janusz, C.A., and Schwartz, R.A., 2006. Vitiligo: a sign of systemic disease. Indian journal of dermatology, venereology and leprology , 72 (1), 68.
   PubMedGoogle Scholar
• Iannella, G., et al., 2016. Vitiligo: pathogenesis, clinical variants and treatment approaches. Autoimmunity reviews, 15 (4), 335–343.
   PubMed Web of Science ®Google Scholar
• Khaitan, B.K., Kathuria, S., and Ramam, M., 2012. A descriptive study to characterize segmental vitiligo. Indian journal of dermatology, venereology, and leprology, 78 (6), 715.
   PubMed Web of Science ®Google Scholar
• Niven, J., et al., 2015. S100B up-regulates macrophage production of IL1β and CCL22 and influences severity of retinal inflammation. PLOS one, 10 (7), e0132688.
   PubMed Web of Science ®Google Scholar
• Perfetti, L., et al., 1991. Prevalence of atopy in vitiligo. Dermatology, 182 (4), 218–220.
   Google Scholar
• Sahni, K., and Parsad, D., 2013. Stability in vitiligo: is there a perfect way to predict it?. Journal of cutaneous and aesthetic surgery, 6 (2), 75.
   PubMedGoogle Scholar
• Schallreuter-Wood, K.U., Pittelkow, M.R., and Swanson, N.N., 1996. Defective calcium transport in vitiliginous melanocytes. Archives of dermatological research, 288 (1), 11–13.
   PubMed Web of Science ®Google Scholar
• Silverberg, N.B., 2015. The epidemiology of vitiligo. Current dermatology reports, 4 (1), 36–43.
   Web of Science ®Google Scholar
• Sirois, C.M., et al., 2014. RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. The journal of experimental medicine, 211 (5), 1001–1001.
   Web of Science ®Google Scholar
• Sorci, G., et al., 2013. S100B protein in tissue development, repair and regeneration. World journal of biological chemistry, 4 (1), 1.
   PubMedGoogle Scholar
• Speeckaert, R., et al., 2017. S100B is a potential disease activity marker in nonsegmental vitiligo. Journal of investigative dermatology, 137 (7), 1445–1453.
   PubMed Web of Science ®Google Scholar
• Strömberg, S., et al., 2008. Transcriptional profiling of melanocytes from patients with vitiligo vulgaris. Pigment cell and melanoma research, 21 (2), 162–171.
   PubMed Web of Science ®Google Scholar
• Taïeb, A., and Picardo, M., 2007. Members oV: the definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment cell research, 20 (1), 27–35.
   PubMedGoogle Scholar
• Teulings, H., et al., 2013. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. British Journal of Dermatology, 168 (1), 162–171.
   PubMed Web of Science ®Google Scholar
• van Geel, N., et al., 2013. The distribution pattern of segmental vitiligo: clues for somatic mosaicism. British journal of dermatology, 168 (1), 56–64.
   PubMed Web of Science ®Google Scholar
• Wagner, R.Y., et al., 2015. Altered E-cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo. Journal of investigative dermatology, 135 (7), 1810–1819.
   PubMed Web of Science ®Google Scholar
• Weide, B., et al., 2013. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PLOS one, 8 (11), e81624.
   PubMed Web of Science ®Google Scholar